GlassScriptPhysician profile
Pierre Asmar
NPI 1538294830
$448.83
in general payments reported to CMS, 2019-2025
7 companies · $48.45 in 2025
The $48.45 reported for 2025 was less than what a typical Reproductive Endocrinology provider received nationally (typical 2025 total: $140).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $45.44 · 2021: $11.23 · 2022: $141 · 2023: $202 · 2025: $48.45.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $251.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $250.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vitrolife INC. | $187.54 | 2023 | |
| Ferring Pharmaceuticals As | $126.88 | 2022 | |
| Coopersurgical, INC. | $65.42 | 2020-2025 | |
| Organon LLC | $25.59 | 2021-2022 | |
| Minerva Surgical, INC | $14.93 | 2023 | |
| Ferring Pharmaceuticals INC. | $14.69 | 2020 | |
| Merck Sharp & Dohme LLC | $13.78 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pierre Asmar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.